Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Optimism Building For Korea's Celltrion Amid Expectations For Biosimilars

This article was originally published in PharmAsia News

Executive Summary

SEOUL - Optimism is building for South Korea's biopharmaceutical firm Celltrion and its biosimilar program, as seen in the recent surge of its stock price
Advertisement

Related Content

Korea's Celltrion To Supply Biosimilars To Europe And Japan This Year, Boosting Forecast
Korea's Celltrion To Supply Biosimilars To Europe And Japan This Year, Boosting Forecast
2011 Preview: Will Korean Pharmas Follow Japanese Pharmas Lead To Survive Harsh Environment At Home?
2011 Preview: Will Korean Pharmas Follow Japanese Pharmas Lead To Survive Harsh Environment At Home?
Korea's Celltrion Eyes Eastern Bloc For Biosimilar Expansion
Korea's Celltrion and Sanofi-Aventis In Line With 2008 Strategic Alliance For Monoclonal Antibodies
Korea's Celltrion and Sanofi-Aventis In Line With 2008 Strategic Alliance For Monoclonal Antibodies
Korea's Celltrion Sells 10 Percent Of Its Shares To Singapore's Temasek To Fund Biosimilar Development
Advertisement
UsernamePublicRestriction

Register

SC073757

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel